BioPharma Dive January 18, 2022
Sponsored content By ICON

Developing drugs is a capital-intensive activity, and never more so than when a biotech company wants to move from preclinical development to more expensive clinical trials. Early on, there are often angel investments and/or academic or government grants, but the most common source when moving into Phase I and II trials is fundraising rounds through syndicates of venture capital funds. It’s a lot to handle for biotech companies, which typically are small startups comprised of scientific founders and researchers.

One of the key intermediary steps is working with contract research organizations (CRO), which are involved in preclinical testing, assay development, animal testing, clinical trial design, drug manufacturing, data analysis and regulatory submissions. What is not as common, but is increasing,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article